Literature DB >> 4943034

Controlled trial of penfluridol in acute psychosis.

H M van Praag, T Schut, L Dols, R van Schilfgaarden.   

Abstract

A controlled study was made of penfluridol medication consisting of a single weekly oral dose of 30 mg in 30 patients with acute psychoses of varying type and origin. This medication was found to be effective. No significant side effects occurred.Several long-acting neuroleptics for injection are now available. The development of an oral compound of this type is an asset because of the manageability of the oral drug in the hands of family doctors and social psychiatrists.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4943034      PMCID: PMC1799991          DOI: 10.1136/bmj.4.5789.710

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  A FOLLOW-UP OF SCHIZOPHRENIC PATIENTS IN EDINBURGH.

Authors:  C A Renton; J W Affleck; G M Carstairs; A D Forrest
Journal:  Acta Psychiatr Scand       Date:  1963       Impact factor: 6.392

2.  A simple and reliable subclassification of chronic schizophrenia.

Authors:  J K WING
Journal:  J Ment Sci       Date:  1961-09

3.  [A long-acting neuroleptic. 3. Pilot study of penfluridol (R 16341)].

Authors:  J Bobon; J Melon; C Mormont; M Dufrasne; A Pinchard
Journal:  Acta Psychiatr Belg       Date:  1970

4.  Maintenance therapy of chronic psychostic patients with a weekly oral dose of R 16 341. A controlled double-blind study.

Authors:  F Baro; J Brugmans; R Dom; R Van Lommel
Journal:  J Clin Pharmacol J New Drugs       Date:  1970 Sep-Oct

5.  Dexbenzetimide in neuroleptic-induced parkinsonism. A double-blind crossover study with a 16-week follow-up.

Authors:  R De Smedt; E Rodrigus; R Debandt; J Brugmans
Journal:  J Clin Pharmacol J New Drugs       Date:  1970 May-Jun

6.  Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication.

Authors:  R F Prien; J O Cole; N F Belkin
Journal:  Br J Psychiatry       Date:  1969-06       Impact factor: 9.319

7.  The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug.

Authors:  P A Janssen; C J Niemegeers; K H Schellekens; F M Lenaerts; F J Verbruggen; J M van Nueten; R H Marsboom; V V Hérin; W K Schaper
Journal:  Arzneimittelforschung       Date:  1970-11
  7 in total
  9 in total

Review 1.  Clinical use of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs.

Authors:  L E Hollister
Journal:  Drugs       Date:  1972       Impact factor: 9.546

2.  What's new in the psychopharmacology of schizophrenia.

Authors:  A Rifkin; F Quitkin
Journal:  Bull N Y Acad Med       Date:  1978-10

Review 3.  Chlorpromazine versus penfluridol for schizophrenia.

Authors:  Naemeh Nikvarz; Mostafa Vahedian; Navid Khalili
Journal:  Cochrane Database Syst Rev       Date:  2017-09-23

4.  Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?

Authors:  Sofia Brissos; David Taylor
Journal:  CNS Drugs       Date:  2022-02-28       Impact factor: 5.749

5.  Penfluridol: an open phase III study in acute newly admitted hospitalized schizophrenic patients.

Authors:  B Shopsin; H Klein; L Gerbino; G Selzer
Journal:  Psychopharmacology (Berl)       Date:  1977-12-19       Impact factor: 4.530

6.  Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis.

Authors:  Xianghai Zeng; Pengfei She; Linying Zhou; Shijia Li; Zubair Hussain; Lihua Chen; Yong Wu
Journal:  Microbiologyopen       Date:  2020-12-20       Impact factor: 3.904

7.  The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.

Authors:  Arnold P M van der Lee; Ibrahim Önsesveren; André I Wierdsma; Roos van Westrhenen; Aartjan T F Beekman; Lieuwe de Haan; Niels C L Mulder
Journal:  CNS Drugs       Date:  2021-04-10       Impact factor: 5.749

Review 8.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

9.  Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases.

Authors:  Yue-Hong Chen; Rong-Han Liu; Ya-Zhou Cui; Aubryanna Hettinghouse; Wen-Yu Fu; Lei Zhang; Chen Zhang; Chuan-Ju Liu
Journal:  Arthritis Res Ther       Date:  2022-01-19       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.